Denosumab for Management of Hypercalcemia in Primary Hyperparathyroidism

Abstract

Denosumab is a completely human monoclonal high-affinity antibody that binds to the nuclear factor kappa-B ligand (RANKL) and is widely used to treat osteoporosis. Furthermore, it can potentially lower serum calcium levels by inhibiting osteoclast activation and preventing bone calcium from being released into the blood. This review aimed to provide evidence of the efficacy and safety of denosumab in treating hypercalcemia in primary hyperparathyroidism (PHPT). PubMed and the Cochrane Library were searched for published studies that described denosumab for hypercalcemia management in PHPT. Data were extracted by two independent investigators and analyzed using SPSS 23. The risk of bias was assessed by NIH Quality Assessment Tool. In total, 161 patients with PHPT from 18 studies were included in this review. The average age was 61 (47–72) years and the highest serum calcium was 3.76 (3.11–4.20) mmol/l. We found that denosumab can effectively reduce the serum calcium level by a median reduction of 0.5 mmol/l within 3 days. Significant reduction was maintained for 14 days. The serum calcium-lowering effect weakened after one month. In conclusion, denosumab has a potential clinical value in treating hypercalcemia in patients with PHPT.

Keywords

denosumab - calcium homeostasis - hypercalcemia - hyperparathyroidism

Publikationsverlauf

Eingereicht: 02. Juli 2024

Angenommen nach Revision: 01. September 2024

Artikel online veröffentlicht:
11. Oktober 2024

• References

• 1 Walker MD, Silverberg SJ. Primary hyperparathyroidism. Nat Rev Endocrinol 2018; 14: 115-125
• 2 Ziegler R. Hypercalcemic crisis. J Am Soc Nephrol 2001; 12: S3-S9
• 3 Wilhelm SM, Wang TS, Ruan DT. et al. The American association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism. JAMA Surg 2016; 151: 959-968
• 4 Pappachan JM, Lahart IM, Viswanath AK. et al. Parathyroidectomy for adults with primary hyperparathyroidism. Cochrane Database Syst Rev 2023; 3: Cd013035
• 5 Cummings SR, San Martin J, McClung MR. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765
• 6 Kendler DL, Cosman F, Stad RK. et al. Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther 2022; 39: 58-74
• 7 Bollerslev J, Rejnmark L, Zahn A. et al. European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE educational program of parathyroid disorders. Eur J Endocrinol 2022; 186: R33-R63
• 8 Eller-Vainicher C, Palmieri S, Cairoli E. et al. Protective effect of denosumab on bone in older women with primary hyperparathyroidism. J Am Geriatr Soc 2018; 66: 518-524
• 9 Eremkina A, Krupinova J, Dobreva E. et al. Denosumab for management of severe hypercalcemia in primary hyperparathyroidism. Endocr Connect 2020; 9: 1019-1027
• 10 Gronskaya S, Belaya Z, Rozhinskaya L. et al. Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency. Endocrine 2023; 81: 368-378
• 11 Leere JS, Karmisholt J, Robaczyk M. et al. Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2020; 8: 407-417
• 12 Miyaoka D, Imanishi Y, Kato E. et al. Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism. Endocrine 2020; 69: 642-649
• 13 Çalapkulu M, Gul OO, Cander S. et al. Control of refractory hypercalcemia with denosumab in a case of metastatic parathyroid carcinoma. J Coll Physicians Surg Pak 2020; 30: 757-759
• 14 Gill G, Agrawal V, Kerr P. Primary hyperparathyroidism presenting as acute hypercalcemic crisis: a case report. J Otolaryngol Head Neck Surg 2023; 52: 1
• 15 Jumpertz von Schwartzenberg R, Elbelt U, Ventz M. et al. Palliative treatment of uncontrollable hypercalcemia due to parathyrotoxicosis: denosumab as rescue therapy. Endocrinol Diabetes Metab Case Rep 2015; 2015: 150082
• 16 Kuchay MS, Mathew A, Kaur P. et al. Denosumab can be used successfully as a bridge to surgery in patients with severe hypercalcemia due to primary hyperparathyroidism. Arch Endocrinol Metab 2021; 65: 669-673
• 17 Lenherr-Taube N, Lam CK, Vali R. et al. Severe primary hyperparathyroidism caused by parathyroid carcinoma in a 13-year-old child; novel findings from HRpQCT. JBMR Plus 2020; 4: e10324
• 18 Li Y, Fan CY, Manni A. et al. Pitfalls of using denosumab preoperatively to treat refractory severe hypercalcaemia. BMJ Case Rep 2020; 13: e233665
• 19 Makino H, Notsu M, Asayama I. et al. Successful control of hypercalcemia with sorafenib, evocalcet, and denosumab combination therapy for recurrent parathyroid carcinoma. Intern Med 2022; 61: 3383-3390
• 20 Omi Y, Yamamoto T, Nagashima Y. et al. Parathyroid carcinoma in a 13-year-old girl with a long-term survival. Surg Case Rep 2020; 6: 145
• 21 Rajan R, Cherian KE, Kapoor N. et al. Denosumab as a bridge to surgery in a patient with severe hypercalcemia due to primary hyperparathyroidism in the setting of renal dysfunction. Indian J Endocrinol Metab 2019; 23: 269-270
• 22 Roukain A, Alwan H, Bongiovanni M. et al. Denosumab for the treatment of hypercalcemia in a patient with parathyroid carcinoma: a case report. Front Endocrinol (Lausanne) 2021; 12: 794988
• 23 Shalaby T, Anandappa S, Sivappriyan S. et al. The use of denosumab in a nonagenarian with primary hyperparathyroidism. Eur Endocrinol 2014; 10: 151-152
• 24 Tzotzas T, Goropoulos A, Karras S. et al. Effective long-term management of parathyromatosis-related refractory hypercalcemia with a combination of denosumab and cinacalcet treatment. Hormones (Athens) 2022; 21: 171-176
• 25 Vellanki P, Lange K, Elaraj D. et al. Denosumab for management of parathyroid carcinoma-mediated hypercalcemia. J Clin Endocrinol Metab 2014; 99: 387-390
• 26 Kim SY, Ok HG, Birkenmaier C. et al. Can denosumab be a substitute, competitor, or complement to bisphosphonates?. Korean J Pain 2017; 30: 86-92
• 27 Ahmad S, Kuraganti G, Steenkamp D. Hypercalcemic crisis: a clinical review. Am J Med 2015; 128: 239-245
• 28 Allgrove J. Biphosphonates. Arch Dis Child 1997; 76: 73-75
• 29 Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int 2008; 74: 1385-1393
• 30 Body JJ, Pfister T, Bauss F. Preclinical perspectives on bisphosphonate renal safety. Oncologist 2005; 10: 3-7
• 31 Chandran M, Bilezikian JP, Lau J. et al. The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies. Rev Endocr Metab Disord 2022; 23: 485-501
• 32 Manaka K, Sato J, Kinoshita Y. et al. Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience. Endocr J 2019; 66: 683-689
• 33 Peacock M, Bolognese MA, Borofsky M. et al. Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 2009; 94: 4860-4867
• 34 Raje N, Terpos E, Willenbacher W. et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol 2018; 19: 370-381
• 35 Bandeira F, Cusano NE, Silva BC. et al. Bone disease in primary hyperparathyroidism. Arq Bras Endocrinol Metabol 2014; 58: 553-561